Good morning :)
$
₹
Fulcrum Therapeutics Inc

Fulcrum Therapeutics Inc

FULC

NASDAQ
Asset Logo

Fulcrum Therapeutics Inc

FULC

NASDAQ
$3.770.29% (-0.01)
$
₹
$3.770.29% (-0.01)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $289.9M the stock is ranked 3905

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.93
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-1.21
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 7 analysts' reports

Buy
3 analysts
Hold
3 analysts
Sell
1 analyst

Analysts expect a -7.41% price downside over the next year

Current Price$3.77
Target Price$3.5

Company Profile

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Peers

Peers

Eli Lilly and Company
LLY
Eli Lilly and Company
P/E Ratio
37.45
37.45
1Y Return
52.07%
52.07%
Buy Reco %
77.41
77.41
Johnson & Johnson
JNJ
Johnson & Johnson
P/E Ratio
30.77
30.77
1Y Return
51.57%
51.57%
Buy Reco %
45.83
45.83
Merck & Company Inc
MRK
Merck & Company Inc
P/E Ratio
115.14
115.14
1Y Return
77.47%
77.47%
Buy Reco %
57.69
57.69
Novartis AG ADR
NVS
Novartis AG ADR
P/E Ratio
20.71
20.71
1Y Return
12.41%
12.41%
Buy Reco %
15.38
15.38
AstraZeneca PLC
AZN
AstraZeneca PLC
P/E Ratio
23.97
23.97
1Y Return
4.7%
4.7%
Buy Reco %
90.00
90.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Fulcrum Therapeutics Inc -0.93-
Eli Lilly and Company37.4529.351.10
Johnson & Johnson30.777.532.78

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

-19.5
-20.3
-18.8
-26.1
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue08000000000
Net Income-26.8755.40-21.69-16.56-17.65-17.29-19.59-20.33-18.89-26.17
Net Profit Margin-69.26%--------
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Fulcrum Therapeutics Inc (FULC) share price today is $3.77 as of September 16, 2026 at 1:30 AM IST. The stock touched a day high of $3.79 and a day low of $3.75.

  2. Fulcrum Therapeutics Inc stock trades on NASDAQ under the ticker symbol FULC.

  3. Fulcrum Therapeutics Inc's market capitalization is $289.92M as of September 16, 2026 at 1:30 AM IST.

  4. Fulcrum Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of September 15, 2026.

  5. Fulcrum Therapeutics Inc's price-to-book (P/B) ratio is 0.93 as of September 15, 2026.

  6. Yes, You can buy Fulcrum Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Fulcrum Therapeutics Inc shares in three steps: 1. Search Fulcrum Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Fulcrum Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Fulcrum Therapeutics Inc (FULC) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.6462 shares at the current price of $3.77.

Loading...